Clinical Trial Update: A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases [Phase 2]

View source ↗

Summary

Phase 2 study compares encorafenib + binimetinib + nivolumab versus ipilimumab + nivolumab in BRAF-V600 mutation melanoma with brain metastases; recruitment is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acral Lentiginous Melanoma
• Cutaneous Melanoma
• Melanoma
• Melanoma with Brain Metastases
• Mucosal Melanoma

Drugs mentioned

• BRAFTOVI (ENCORAFENIB)
• MEKTOVI (BINIMETINIB)
• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Acral Lentiginous Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Status: RECRUITING